



2018年11月30日 星期五

首页

期刊概况

编委会

专家学者

网上投稿

过刊浏览

期刊订阅

广告合作

中国肿瘤临床 2015, Vol. 42 2015, Issue (1): 56-60 DOI: doi:10.3969/j.issn.1000-8179.2014.1672

临床研究与应用

最新目录 | 下期目录 | 过刊浏览 | 高级检索

◀ 前一篇 | 后一篇 ▶

胞浆-5'-核苷酸酶- II 在非小细胞肺癌组织中的表达及其临床意义*

曲莉莉^①, 刘晓晴^①, 王伟霞^①, 汤传昊^①, 李俊杰^①, 李晓燕^①, 高红军^①, 李晓兵^②, 刘广贤^③

作者单位: ①军事医学科学院附属医院肺部肿瘤内科(北京市100071); ②病理科; ③血液内科

Expression and clinical significance of CN- II in non-small cell lung cancer tissues

Lili QU1, Xiaoqing LIU1, Weixia WANG1, Chuanhao TANG1, Jianjie LI1, Xiaoyan LI1, Hongjun GAO1, Xiaobing LI2, Guangxian LIU3

1Department of Lung Cancer,

2Department of Pathology,

3Department of Hematology, the Affiliated Hospital of the Academy of Military Medical Science, Beijing 100071, China

摘要

图表

参考文献(0)

相关文章(15)

全文: PDF (1553 KB) HTML (1 KB)

输出: BibTeX | EndNote (RIS)

摘要

目的: 胞浆-5'-核苷酸酶- II (CN- II) 是一种核苷酸酶, 具有水解酶及磷酸转移酶的活性, 其异常表达可能与多种核苷类药物耐药有一定相关性。本研究旨在探讨CN- II在非小细胞肺癌(non-small cell lung cancer, NSCLC)组织中的表达及其与临床病理因素的关系。方法: 应用免疫组织化学方法检测116例NSCLC原发及转移灶中CN- II的表达并分析其中67例曾接受过吉西他滨方案化疗的患者其CN- II表达与吉西他滨近期疗效及生存的相关性, 采用 χ^2 检验及Fisher精确检验分析其表达水平与临床病理因素的相关性, 采用Kaplan-Meier方法分析TTP及OS(overall survival, OS), 采用对数秩和检验比较不同CN- II表达情况之间的差异。结果: 116例NSCLC标本中CN- II阳性表达率为53.4%, 其表达水平与患者的年龄、性别、KPS评分、临床分期、肿瘤病理类型及分化程度等均无显著相关性。NSCLC原发病灶与淋巴结等转移灶中CN- II的表达水平亦无显著性差异。对67例接受含吉西他滨方案化疗NSCLC患者肿瘤组织标本的检测发现, 吉西他滨化疗有效组(CR+PR)、疾病控制组(CR+PR+SD)及无效组(PD)的CN- II阳性表达率分别为30.4%、36.7%及57.6%, 前两者与后者相比均有显著性差异(CR+PR vs. PD组, $P=0.008$; CR+PR+SD vs. PD组, $P=0.013$); 28例CN- II阳性及39例阴性患者中位肿瘤进展时间(progression free survival, PFS)分别为4.0个月及5.5个月, 有显著性差异(95%CI: 4.452-6.148, $P=0.041$), 两组患者中位OS分别为9.5个月及11.0个月, 无显著性差异(95%CI: 8.667-13.333, $P=0.282$)。结论: CN- II异常表达与吉西他滨治疗疗效有一定相关性, 有可能成为潜在的疗效预测因子。

关键词: 5'-核苷酸酶, 吉西他滨, 耐药性, 非小细胞肺癌

Abstract:

Objective: Cytosolic 5'-nucleotidase (CN- II), a nucleotide kinase, exhibits both 5'-nucleotidase and nucleoside phosphotransferase activities. Abnormal CN- II expression may be correlated with the resistance of nucleoside analogs in anticancer drugs. This study was designed to investigate CN- II expression in human non-small cell lung cancer (NSCLC) tissues and its correlation with the clinicopathological parameters as well as the prognosis of patients treated with gemcitabine. Methods: Immunohistochemistry was used to detect CN- II expression in 116 cases of paraffin-embedded NSCLC samples. The correlations with the clinicopathological parameters and the response to gemcitabine chemotherapy of CN- II were analyzed through the Chi-square test. Log-rank test was used to determine whether or not CN- II expression is correlated with the overall survival of patients. Results: The positive rate of CN- II was 53.4% in 116 NSCLC tissues. No significant correlation existed between CN- II expression and the clinicopathological parameters. Among the 67 of the 116 patients who received gemcitabine chemotherapy, those with tumor progression (positive rate of 57.6%) exhibited higher CN- II expression than those with therapeutic efficacy (positive rate of 30.4%, $P=0.008$) and disease-control chemotherapy (positive rate of 36.7%, $P=0.013$). The progression-free survival was 4.5 and 5.5 months in the CN- II-positive and CN- II-negative groups, respectively, with significant differences (95% CI: 4.452 to 6.148, $P=0.041$). Correspondingly, the overall survival was 9.5 and 11.0 months in the two groups (95% CI: 8.667 to 13.333, $P=0.282$). Conclusion: CN- II may be a prognostic factor for gemcitabine chemotherapy in NSCLC patients.

Key words: cytosolic 5'-nucleotidase gemcitabine resistance non-small cell lung cancer

收稿日期: 2014-10-07 出版日期: 2015-01-15

基金资助:

本文课题受首都医学发展科研基金(编号: 2007-3042)资助

通讯作者: 刘晓晴 E-mail: liuxq@medmail.com.cn

引用本文:

曲莉莉^①, 刘晓晴^①, 王伟霞^①, 汤传昊^①, 李俊杰^①, 李晓燕^①, 高红军^①, 李晓兵^②, 刘广贤^③. 胞浆-5'-核苷酸酶- II 在非小细胞肺癌组织中的表达及其临床意义*[J]. 中国肿瘤临床, 2015, 42(1): 56-60. Lili QU1, Xiaoqing LIU1, Weixia WANG1, Chuanhao TANG1, Jianjie LI1, Xiaoyan LI1, Hongjun GAO1, Xiaobing LI2, Guangxian LIU3. Expression and clinical significance of CN- II in non-small cell lung cancer tissues. Chinese Journal of Clinical Oncology, 2015, 42(1): 56-60.

服务

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert
- ▶ RSS

作者相关文章

- ▶ 曲莉莉^①
- ▶ 刘晓晴^①
- ▶ 王伟霞^①
- ▶ 汤传昊^①
- ▶ 李俊杰^①
- ▶ 李晓燕^①
- ▶ 高红军^①
- ▶ 李晓兵^②
- ▶ 刘广贤^③

链接本文:

<http://www.cjco.cn/CN/doi:10.3969/j.issn.1000-8179.20141672> 或 <http://www.cjco.cn/CN/Y2015/V42/I1/56>

友情链接



版权所有 © 2013 《中国肿瘤临床》编辑部

地址：天津市河西区体院北环湖西路肿瘤医院内 300060

电话/传真：(022)23527053 E-mail: cjco@cjco.cn cjcotj@sina.com 津ICP备09011441号-3